Bristol-Myers Squibb BMY Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $9.57B-12.0% | $10.21B-1.3% | $15.73B+99.3% | $12.6B+100% | $10.88B+16.6% | ||
| $912M+0.6% | $464M-9.6% | $776M+280% | $1B+179% | $907M+167% | ||
| $9.37B-13.3% | $11.41B+6.2% | $11.42B+3.6% | $11.42B-0.1% | $10.8B+3.4% | ||
| $2.76B+3.4% | $2.69B+5.2% | $2.76B-17.2% | $2.74B-11.0% | $2.67B-10.7% | ||
| $27.21B-11.6% | $29.39B-1.3% | $35.63B+26.9% | $33.22B+23.5% | $30.78B+7.4% | ||
| $7.66B+6.2% | $7.54B+5.7% | $7.35B+6.5% | $7.37B+7.7% | $7.21B+6.9% | ||
| $21.74B0.0% | $21.75B+0.2% | $21.75B0.0% | $21.78B+0.2% | $21.74B0.0% | ||
| $161M-96.0% | -$392M-109% | $4.96B+37.5% | $4.65B+39.8% | $4B+46.8% | ||
| $86.48B-6.4% | $90.04B-2.8% | $96.89B+3.4% | $94.68B0.0% | $92.43B-6.7% | ||
| $4.23B+5.8% | $3.58B-0.7% | $4.29B+23.6% | $5.43B+44.7% | $4B+13.1% | ||
| $2.31B-35.1% | $2.26B+10.5% | $4.51B+318% | $4.72B+33.5% | $3.55B-42.6% | ||
| $199M+15.7% | $202M+11.6% | $214M+29.7% | $194M+9.6% | $172M+1.8% | ||
| $2.31B-35.1% | $2.26B+10.5% | $4.51B+318% | $4.72B+33.5% | $3.55B-42.6% | ||
| $187M+246% | -$324M— | $887M+355% | -$621M+68.0% | $54M-94.1% | ||
| $19.16B-20.4% | $23.42B-1.5% | $28.14B+24.3% | $27.53B+18.3% | $24.07B-6.8% | ||
| $42.15B-8.7% | $42.85B-10.0% | $44.47B-8.6% | $44.47B-9.0% | $46.16B-6.7% | ||
| $4.85B+8.4% | $5.04B+12.8% | $5.46B+15.5% | $4.94B-1.0% | $4.48B-33.5% | ||
| $66.37B-11.5% | $71.53B-6.1% | $78.29B+2.4% | $77.19B-0.5% | $74.98B-9.1% | ||
| $292M0.0% | $292M0.0% | $292M0.0% | $292M0.0% | $292M0.0% | ||
| $46.37B+0.8% | $46.39B+0.8% | $46.27B+0.8% | $46.13B+0.8% | $46.01B+0.8% | ||
| $18.29B+13.5% | $16.9B+13.3% | $17.09B+6.2% | $16.15B+0.3% | $16.11B+3.0% | ||
| -$1.37B+3.8% | -$1.52B-23.1% | -$1.51B-3.1% | -$1.55B-6.7% | -$1.42B-1.7% | ||
| $43.52B-0.2% | $43.58B-0.2% | $43.59B-0.2% | $43.59B-0.2% | $43.6B-0.2% | ||
| $20.07B+15.4% | $18.47B+13.1% | $18.55B+8.2% | $17.44B+2.5% | $17.39B+5.5% | ||
| $86.48B-6.4% | $90.04B-2.8% | $96.89B+3.4% | $94.68B0.0% | $92.43B-6.7% | ||
| $912M+0.6% | $464M-9.6% | $776M+280% | $1B+179% | $907M+167% | ||
| $4.6B-16.9% | $4.61B-17.9% | $4.95B-12.0% | $5.47B-4.7% | $5.53B-0.6% | ||
| $6.08B+3.7% | $6.47B+6.0% | $6.33B+4.8% | $5.94B-2.2% | $5.87B-2.6% | ||
| $366M+6.4% | $396M+23.8% | $406M+25.3% | $346M-3.1% | $344M-6.3% | ||
| $5.18B+29.5% | $5.38B+27.0% | $4.96B+37.5% | $4.65B+39.8% | $4B+46.8% | ||
| $18.24B-18.9% | $19.1B-18.0% | $20.47B-24.1% | $21.38B-27.4% | $22.49B-31.4% | ||
| $6.08B+3.7% | $6.47B+6.0% | $6.33B+4.8% | $5.94B-2.2% | $5.87B-2.6% | ||
| $6.08B+3.7% | $6.47B+6.0% | $6.33B+4.8% | $5.94B-2.2% | $5.87B-2.6% | ||
| $12.62B-23.6% | $17.58B-3.0% | $19.34B+6.9% | $17.39B+8.8% | $16.51B+2.6% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $2.31B-35.1% | $2.26B+10.5% | $4.51B+318% | $4.72B+33.5% | $3.55B-42.6% | ||
| $211M-23.6% | $222M-39.8% | $225M-47.7% | $247M-46.4% | $276M-37.6% | ||
| $34M-42.4% | $33M-37.7% | $48M-17.2% | $54M0.0% | $59M+1.7% | ||
| —— | 2.5K-12.5% | —— | —— | —— | ||
| —— | 2.5K-12.5% | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Bristol-Myers Squibb's total assets?
- Bristol-Myers Squibb (BMY) holds $86.5B in total assets, down 6.4% year over year.
- How much debt does Bristol-Myers Squibb have?
- Bristol-Myers Squibb carries $44.7B in total debt against $20.1B of shareholders' equity, a debt-to-equity ratio of 2.23.
- How much cash does Bristol-Myers Squibb have?
- Bristol-Myers Squibb holds $9.6B in cash and equivalents.
- Can Bristol-Myers Squibb cover its short-term obligations?
- Its current ratio is 1.42 — current assets exceed current liabilities.
- Where does Bristol-Myers Squibb's balance sheet data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
